Today’s items connect the clinical-access question for individualized neoantigen therapy in lung cancer with a methodological framework for turning tumor molecular identity into vaccine targets.
The common thread is that neoantigen cancer vaccines require both patient-relevant trial design and rigorous AI/multi-omics validation to move from predicted antigens to clinically useful immunotherapy.Black DoctorFrontiers
Nothing published in the last 14 days cleared the bar. Below is the most relevant background we're tracking.
Relevant work from earlier we're still surfacing — not today's news.